The UK Medical Eligibility Criteria for Contraceptive Use states that women who are breastfeeding and less than 6 weeks postpartum should not use the combined oral contraceptive pill as it can reduce breast milk volume. However, from 6 weeks to 6 months postpartum, it is classified as UKMEC 2 and can be used. It is important to note that exclusive breastfeeding can act as an effective contraceptive method. The Mirena intrauterine system and copper IUD can be used from 4 weeks postpartum, while the progesterone-only pill can be started on or after day 21 postpartum. The progesterone-only implant can be inserted at any time, but contraception is not necessary before day 21 postpartum.

After giving birth, women need to use contraception after 21 days. The progesterone-only pill (POP) can be started at any time postpartum, according to the FSRH. Additional contraception should be used for the first two days after day 21. A small amount of progesterone enters breast milk, but it is not harmful to the infant. On the other hand, the combined oral contraceptive pill (COCP) is absolutely contraindicated (UKMEC 4) if breastfeeding is less than six weeks post-partum. If breastfeeding is between six weeks and six months postpartum, it is a UKMEC 2. The COCP may reduce breast milk production in lactating mothers. It should not be used in the first 21 days due to the increased venous thromboembolism risk post-partum. After day 21, additional contraception should be used for the first seven days. The intrauterine device or intrauterine system can be inserted within 48 hours of childbirth or after four weeks.

The lactational amenorrhoea method (LAM) is 98% effective if the woman is fully breastfeeding (no supplementary feeds), amenorrhoeic, and less than six months post-partum. It is important to note that an inter-pregnancy interval of less than 12 months between childbirth and conceiving again is associated with an increased risk of preterm birth, low birth weight, and small for gestational age babies.

Managing Chickenpox in Pregnancy: Treatment and Care

Chickenpox is a common childhood disease caused by the varicella-zoster virus. When a pregnant woman contracts chickenpox, it can have detrimental effects on the fetus. However, with proper management and care, the risk of complications can be minimized.

Oral acyclovir is recommended for pregnant women who develop chickenpox within 24 hours of the rash appearing and are at or over 20 weeks’ gestation. Symptomatic relief, such as adequate fluid intake, wearing light cotton clothing, and using paracetamol or soothing moisturizers, can also help alleviate discomfort.

Immediate admission to secondary care is necessary for women with severe symptoms, immunosuppression, haemorrhagic rash, or neurological or respiratory symptoms. Women with mild disease can be cared for in the community and should avoid contact with susceptible individuals until the rash has crusted over.

An immediate fetal growth scan is not necessary unless there are other obstetric indications or concerns. Women who develop chickenpox in pregnancy should have a fetal growth scan at least 5 weeks after the primary infection to detect any possible fetal defects.

Varicella immunisation is not useful in this scenario, as it is a method of passive protection against chickenpox and not a treatment. Termination of pregnancy is not indicated for chickenpox in pregnancy, but the patient should be informed of the risks to the fetus and possible congenital abnormalities.

Overall, proper management and care can help minimize the risk of complications from chickenpox in pregnancy. It is important for pregnant women to seek medical care if symptoms worsen or if there are any concerns.

It is not advisable to conduct a digital vaginal examination in cases of suspected placenta praevia without first performing an ultrasound, as this could potentially trigger a dangerous hemorrhage.

Understanding Placenta Praevia

Placenta praevia is a condition where the placenta is located wholly or partially in the lower uterine segment. It is a relatively rare condition, with only 5% of women having a low-lying placenta when scanned at 16-20 weeks gestation. However, the incidence at delivery is only 0.5%, as most placentas tend to rise away from the cervix.

There are several factors associated with placenta praevia, including multiparity, multiple pregnancy, and embryos implanting on a lower segment scar from a previous caesarean section. Clinical features of placenta praevia include shock in proportion to visible loss, no pain, a non-tender uterus, abnormal lie and presentation, and a usually normal fetal heart. Coagulation problems are rare, and small bleeds may occur before larger ones.

Diagnosis of placenta praevia should not involve digital vaginal examination before an ultrasound, as this may provoke severe haemorrhage. The condition is often picked up on routine 20-week abdominal ultrasounds, but the Royal College of Obstetricians and Gynaecologists recommends the use of transvaginal ultrasound for improved accuracy and safety. Placenta praevia is classified into four grades, with grade IV being the most severe, where the placenta completely covers the internal os.

In summary, placenta praevia is a rare condition that can have serious consequences if not diagnosed and managed appropriately. It is important for healthcare professionals to be aware of the associated factors and clinical features, and to use appropriate diagnostic methods for accurate grading and management.

The most probable diagnosis in this case is HELLP syndrome, which is a severe form of pre-eclampsia characterized by haemolysis, elevated liver enzymes, and low platelets. While hypertension, vomiting, and abdominal pain can support the diagnosis, they are not mandatory. The abdominal pain may indicate liver inflammation and stretching of the liver capsule.

Intense pruritus is the primary symptom of obstetric cholestasis, and a rise in serum bile acids is the most sensitive marker. Acute fatty liver is another severe condition associated with pre-eclampsia, which causes higher elevations in liver enzymes and deep jaundice. Hyperuricaemia can be a useful marker of pre-eclampsia and does not necessarily indicate gout. Urate levels increase due to reduced kidney function and clearance. Hyperemesis gravidarum is unlikely to present for the first time this late in pregnancy and should be a diagnosis of exclusion.

Pre-eclampsia is a condition that occurs during pregnancy and is characterized by high blood pressure, proteinuria, and edema. It can lead to complications such as eclampsia, neurological issues, fetal growth problems, liver involvement, and cardiac failure. Severe pre-eclampsia is marked by hypertension, proteinuria, headache, visual disturbances, and other symptoms. Risk factors for pre-eclampsia include hypertension in a previous pregnancy, chronic kidney disease, autoimmune disease, diabetes, chronic hypertension, first pregnancy, and age over 40. Aspirin may be recommended for women with high or moderate risk factors. Treatment involves emergency assessment, admission for observation, and medication such as labetalol, nifedipine, or hydralazine. Delivery of the baby is the most important step in management, with timing depending on the individual case.

This patient has intrahepatic cholestasis of pregnancy, which is characterized by abnormal liver function tests and severe itching in the third trimester. This condition increases the risk of stillbirth and maternal complications, particularly after 37 weeks of gestation. Therefore, induction of labor is typically recommended at this point, especially for patients with elevated transaminases and bile acids. While increased fetal monitoring is advised, hospitalization is not necessary unless there are signs of immediate concern for the fetus. A vaginal birth is usually appropriate, and a cesarean section is rarely required unless there are indications of non-reassuring fetal status. Although antihistamines can provide symptomatic relief, they are not sufficient on their own due to the risks associated with this condition. Other options for symptom relief include ursodeoxycholic acid, cholestyramine, and topical emollients. There is no indication for immediate delivery, as fetal movements and ultrasound results are normal.

Intrahepatic Cholestasis of Pregnancy: Symptoms and Management

Intrahepatic cholestasis of pregnancy, also known as obstetric cholestasis, is a condition that affects approximately 1% of pregnancies in the UK. It is characterized by intense itching, particularly on the palms, soles, and abdomen, and may also result in clinically detectable jaundice in around 20% of patients. Raised bilirubin levels are seen in over 90% of cases.

The management of intrahepatic cholestasis of pregnancy typically involves induction of labor at 37-38 weeks, although this practice may not be evidence-based. Ursodeoxycholic acid is also widely used, although the evidence base for its effectiveness is not clear. Additionally, vitamin K supplementation may be recommended.

It is important to note that the recurrence rate of intrahepatic cholestasis of pregnancy in subsequent pregnancies is high, ranging from 45-90%. Therefore, close monitoring and management are necessary for women who have experienced this condition in the past.

Hypertension during pregnancy is a common occurrence that requires careful management. In normal pregnancies, blood pressure tends to decrease in the first trimester and then gradually increase to pre-pregnancy levels by term. However, in cases of hypertension during pregnancy, the systolic blood pressure is usually above 140 mmHg or the diastolic blood pressure is above 90 mmHg. Additionally, an increase of more than 30 mmHg systolic or 15 mmHg diastolic from the initial readings may also indicate hypertension.

There are three categories of hypertension during pregnancy: pre-existing hypertension, pregnancy-induced hypertension (PIH), and pre-eclampsia. Pre-existing hypertension refers to a history of hypertension before pregnancy or elevated blood pressure before 20 weeks gestation. PIH occurs in the second half of pregnancy and resolves after birth. Pre-eclampsia is characterized by hypertension and proteinuria, and may also involve edema.

The management of hypertension during pregnancy involves the use of antihypertensive medications such as labetalol, nifedipine, and hydralazine. In cases of pre-existing hypertension, ACE inhibitors and angiotensin II receptor blockers should be stopped immediately and alternative medications should be prescribed. Women who are at high risk of developing pre-eclampsia should take aspirin from 12 weeks until the birth of the baby. It is important to carefully monitor blood pressure and proteinuria levels during pregnancy to ensure the health of both the mother and the baby.

When managing placental abruption in a case where the fetus is alive, less than 36 weeks old, and not displaying any signs of distress, the appropriate course of action is to admit the patient and administer steroids. Admitting the patient is necessary for monitoring and providing necessary care. Steroids are given to aid in the maturation of fetal lungs. It is recommended to deliver the baby at 37-38 weeks due to the increased risk of stillbirth. Tocolytics are not routinely given due to their controversial nature and potential for maternal cardiovascular side effects. Discharging the patient with safety netting is not appropriate as the patient is symptomatic. Activating the major haemorrhage protocol, calling 2222, and performing an emergency caesarean section are not the most suitable options as the patient is not hypotensive and there are no signs of fetal distress.

Placental Abruption: Causes, Management, and Complications

Placental abruption is a condition where the placenta separates from the uterine wall, leading to maternal haemorrhage. The severity of the condition depends on the extent of the separation and the gestational age of the fetus. Management of placental abruption is crucial to prevent maternal and fetal complications.

If the fetus is alive and less than 36 weeks, immediate caesarean delivery is recommended if there is fetal distress. If there is no fetal distress, close observation, administration of steroids, and no tocolysis are recommended. The decision to deliver depends on the gestational age of the fetus. If the fetus is alive and more than 36 weeks, immediate caesarean delivery is recommended if there is fetal distress. If there is no fetal distress, vaginal delivery is recommended. If the fetus is dead, vaginal delivery should be induced.

Placental abruption can lead to various maternal complications, including shock, disseminated intravascular coagulation (DIC), renal failure, and postpartum haemorrhage (PPH). Fetal complications include intrauterine growth restriction (IUGR), hypoxia, and death. The condition is associated with a high perinatal mortality rate and is responsible for 15% of perinatal deaths.

In conclusion, placental abruption is a serious condition that requires prompt management to prevent maternal and fetal complications. Close monitoring and timely intervention can improve the prognosis for both the mother and the baby.

Folic Acid Supplementation in Pregnancy

Explanation: Folic acid supplementation is recommended for all women who are trying to conceive and during pregnancy to reduce the risk of neural tube defects and other congenital abnormalities. The recommended dose is 400 micrograms daily from the preconception period until the 12th week of gestation. However, women with certain high-risk factors, such as diabetes, a family history of neural tube defects, or obesity, are advised to take a higher dose of 5 mg daily from the preconception period until the 12th week of gestation. It is important to continue folic acid supplementation until the end of the first trimester to ensure proper formation of the brain and other major organs in the body. Side-effects of folic acid treatment may include abdominal distension, reduced appetite, nausea, and exacerbation of pernicious anaemia.

After a vaginal delivery, the loss of blood exceeding 500 ml is referred to as postpartum haemorrhage.

Understanding Postpartum Haemorrhage

Postpartum haemorrhage (PPH) is a condition where a woman experiences blood loss of more than 500 ml after giving birth vaginally. It can be classified as primary or secondary. Primary PPH occurs within 24 hours after delivery and is caused by the 4 Ts: tone, trauma, tissue, and thrombin. The most common cause is uterine atony. Risk factors for primary PPH include previous PPH, prolonged labour, pre-eclampsia, increased maternal age, emergency Caesarean section, and placenta praevia.

In managing PPH, it is important to involve senior staff immediately and follow the ABC approach. This includes two peripheral cannulae, lying the woman flat, blood tests, and commencing a warmed crystalloid infusion. Mechanical interventions such as rubbing up the fundus and catheterisation are also done. Medical interventions include IV oxytocin, ergometrine, carboprost, and misoprostol. Surgical options such as intrauterine balloon tamponade, B-Lynch suture, ligation of uterine arteries, and hysterectomy may be considered if medical options fail to control the bleeding.

Secondary PPH occurs between 24 hours to 6 weeks after delivery and is typically due to retained placental tissue or endometritis. It is important to understand the causes and risk factors of PPH to prevent and manage this life-threatening emergency effectively.

Different Types of Incisions for Surgical Procedures

There are various types of incisions used for different surgical procedures. Here are some common types of incisions and their uses:

1. Suprapubic Incision: Also known as the Pfannenstiel incision, this is the most common incision used for Gynaecological and obstetric operations like Caesarean sections. It is made at the pubic hairline.

2. Transverse Incision just below the Umbilicus: This incision is usually too superior for a Caesarean section because the scar would be visible and does not provide direct access to the uterus as the Pfannenstiel incision.

3. Right Subcostal Incision: This incision is used to access the gallbladder and biliary tree.

4. Median Longitudinal Incision: This incision is not commonly used because of cosmetic scarring, as well as the fact that the linea alba is relatively avascular and can undergo necrosis if the edges are not aligned and stitched properly.

5. McBurney’s Point Incision: This incision is used to access the vermiform appendix and is made at the McBurney’s point, which is approximately one-third of the distance of a line, the spino-umbilical line, starting at the right anterior superior iliac spine and ending at the umbilicus.

In conclusion, the type of incision used for a surgical procedure depends on the specific needs of the operation and the surgeon’s preference.